Navigation Links
Genoa Pharmaceuticals announces $1.2M Financing
Date:11/8/2012

SAN DIEGO, Nov. 8, 2012 /PRNewswire/ -- Genoa Pharmaceuticals, a biotechnology company developing novel therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF), announced today the completion of a $1.2M financing. Funds from the financing will be used to advance its lead program, GP-101 (aerosol pirfenidone). IPF is a fatal lung disease caused by both genetic and environmental factors resulting in progressive lung scarring and characterized by reduced exercise capacity and chronic cough. IPF affects approximately 200,000 Americans and 135,000 Europeans.

Genoa was founded by Mark Surber, Ph.D., an aerosol development expert formerly with Mpex and Aires Pharmaceuticals. Dr. Surber serves as Genoa's President and Chief Scientific Officer. "IPF is a very serious disease with only 20% of patients surviving five years," said Dr. Surber. "Currently, there are no U.S. approved drugs, leaving lung transplant as the only option to extend life. Genoa's approach could be a significant advancement to treat patients with this devastating disease and we are excited about the opportunity to progress GP-101 into development."

Outside the United States, only oral pirfenidone is approved for the treatment of IPF. Sold by InterMune in Europe and Shionogi in Japan, this product has shown promise to extend life. However, the oral drug has been associated with gastrointestinal side effects that limit dosing and challenge patient compliance. To address this unmet need, Genoa has created GP-101 as a proprietary aerosol pirfenidone formulation for direct inhalation delivery to the lung. Compared to the oral medicine, inhaled GP-101 delivers an increased pirfenidone lung dose with improved pharmacokinetic parameters. As inhalation delivers more pirfenidone directly to the lung with reduced gastrointestinal exposure, inhaled GP-101 has the potential to improve the efficacy and safety profile of pirfenidone.

"We are pleased to have raised this initial s
'/>"/>

SOURCE Genoa Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
2. Arisaph Pharmaceuticals Reports Positive Results From Two Safety Clinical Trials For Its Niacin Analog (ARI-3037MO)
3. Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
4. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
5. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
6. Isis Pharmaceuticals To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
7. Vanda Pharmaceuticals Reports Third Quarter 2012 Results
8. Radiopharmaceuticals and Contrast Media: Frost & Sullivan Predicts Market Growth in Europe
9. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
10. Enanta Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
11. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , Aug. 1, 2014 RoundTable ... focused exclusively on the healthcare industry, announced today ... The Lubrizol Corporation ("Lubrizol"). Lubrizol, a Berkshire Hathaway ... and supplies technologies to customers in the global ... transaction were not disclosed. Vesta is ...
(Date:8/1/2014)... Minn. , Aug. 1, 2014 ... medical technologies company, announced today that it has ... held manufacturer of cardiorespiratory diagnostic products based in ... MediSoft has served the European cardiorespiratory diagnostics market ... 2013 revenues of approximately €4.7 million ($6.3 million) ...
(Date:8/1/2014)... , Aug. 1, 2014 Dyadic International, Inc. ... and proprietary technologies are used to develop, manufacture and ... chemical, biopharmaceutical and industrial enzyme industries, announced today that ... quarter ended June 30, 2014 after market close on ... call that day at 5:00 p.m. Eastern Time to ...
Breaking Medicine Technology:RoundTable Healthcare Partners Announces Sale of Vesta Funding, Inc. to The Lubrizol Corporation 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 4Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3
(Date:8/1/2014)... August 01, 2014 Stryker hip ... of the 2012 Rejuvenate and ABG II Modular-Neck ... New Jersey’s Bergen County Superior Court, Bernstein Liebhard ... proceeding, the Court has issued a Final ... and all hard copy and electronic materials produced ...
(Date:8/1/2014)... August 01, 2014 Summer is here, and ... active during the summer, and they can be a pain ... ready to help all their customers get rid of ticks ... and 6,000 eggs in the summer, which is why they ... in tall grass and woodland areas and carry a number ...
(Date:8/1/2014)... Washington, DC (PRWEB) August 01, 2014 ... Mike Thompson (D-CA), Gregg Harper (R-MS), and Peter ... H.R. 5380, the Medicare Telehealth Parity Act of ... "We fully support this effort to improve healthcare ... Linkous, chief executive officer of ATA. "These cost-saving ...
(Date:8/1/2014)... The "Antimicrobial Coatings Market by Type (Silver, ... Dioxide, and Zinc Omadine), Application (Indoor air/HVAC, Medical, ... Textiles, and others), & Geography (North America, Europe, ... to 2018" analyzes the Antimicrobial Coatings Market with ... the diverse geographical regions. , Browse 49 market ...
(Date:8/1/2014)... The North America Endpoint Security Market report defines ... America with analysis and forecast of revenue. This market ... 2014 to $4.77 billion by 2019, at a CAGR ... the TOC of the North America Endpoint Security Market ... provided. It also provides a glimpse of the segmentation ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:Tis the Season for Tick Prevention 2Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4
... , ARLINGTON, Va., Oct. 8 The U.S. Centers for ... TriData division, which specializes in public safety research and ... prevention practices in 10 nations. , The study ... reductions in fire deaths and injuries in these nations. ...
... Greater Surface Disinfection to Combat Bad Hygiene , ARLINGTON, Va., ... standing in the lunch line? Or sneeze loudly into the ... (96 percent) have seen you do things like this -- and ... , Even with heightened concerns during this year,s flu season, ...
... ... device, a rapid phase transition gel used in the treatment of Kidney Stones. ... Woburn, Massachusetts (PRWEB) ... alliance with Boston Scientific Corporation (NYSE: BSX) regarding Pluromed,s BackStop™ product, a device used ...
... ... media, cell separation products and ancillary reagents for life science research, is pleased to ... ... 8, 2009 -- STEMCELL Technologies Inc. (STEMCELL), a leader in specialty cell culture media, ...
... ... announces the release of their Mediterranean Diet Resveratrol Formula. , ... Plainview, NY (PRWEB) October ... dietary supplements, announces the release of their Mediterranean Diet Resveratrol Formula., , ,Purity,s ...
... , ... week, the Cheney Research Web site ( www.cheneyresearch.com ) is a multimedia medical Web ... cutting-edge medical concepts and therapies developed at the Cheney Clinic and conveyed in part ... ...
Cached Medicine News:Health News:International Study Finds New Best Practices to Reduce Fire Casualties 2Health News:Gross Germ-Spreading Behaviors Remain the Norm, Despite Flu Season Concerns 2Health News:Gross Germ-Spreading Behaviors Remain the Norm, Despite Flu Season Concerns 3Health News:Pluromed, Inc. Signs Agreement with Boston Scientific 2Health News:Pluromed, Inc. Signs Agreement with Boston Scientific 3Health News:STEMCELL Technologies Inc. Announces Direct Distribution to Spain 2Health News:Purity Products Releases Their Brand New Mediterranean Diet Resveratrol Formula 2Health News:Chronic Fatigue Syndrome and Stem Cell Therapy - Latest Research Available at CheneyResearch.com 2Health News:Chronic Fatigue Syndrome and Stem Cell Therapy - Latest Research Available at CheneyResearch.com 3
... The model 55S Rocking Shaker ... gels and blotted membranes. The very ... adjustable degree of tilt provide a ... washes over gels and blotted membranes ...
... The model 55S Rocking Shaker ... gels and blotted membranes. The very ... adjustable degree of tilt provide a ... washes over gels and blotted membranes ...
Multi-Tier Shaker...
... The Thermo Labsystems Wellmix is a ... and time settings. The shaking speed is ... shaking frequency, high speed and a small ... assays. The shaking time is quick and ...
Medicine Products: